| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net produc... |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Corporate Presentation Sep temb er 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. |
| 09 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 9, 2026, Vera Therapeutics, Inc. (the “Company”) announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as... |
| 07 Jul 2026 |
8-K: Other Events
On July 7, 2026, Vera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin... |
| 02 Jun 2026 |
8-K: Other Events
On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential... |
| 26 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Vera Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 24, 2026, the record date for the Annual Meeting, 71,713,905 shares of Class A common stock were ou... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) ... |
| 09 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 5, 2026, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christopher Hite to the Board, effective immediately. Mr. Hite will serve as a Class III Director, with an initial term expiring ... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 16, 2025, Vera Therapeutics, Inc. (the “Company”) announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025. |
| 10 Dec 2025 |
8-K: Other Events
Vera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”), Goldman Sachs ... |
| 26 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 25, 2025, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed James R. Meyers to the Board, effective immediately. Mr. Meyers will serve as a Class II Director, with an initial term expir... |
| 06 Nov 2025 |
8-K: Other Events
Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received ≥1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed using a mixed-eff... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Atacicept IgA nephropathy (IgAN) ORIGIN 3 trial primary endpoint results selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 |
| 05 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Vera Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of June 2, 2025 (the “Signing Date”), among OXFORD FINANCE LLC, a Delaware limited liability c... |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 ORIGIN Phase 3 Topline Results June 2, 2025 © 2025 Vera Therapeutics, Inc. Corporate Presentation. |
| 19 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2025, Vera Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 17, 2025, the record date for the Annual Meeting, 63,771,720 shares of Class A common stock were ou... |
Loading...